Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

François Ghiringhelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5465-8305; OpenAlex author ID A5043463827. Sources: ClinicalTrials.gov.

Their work

Papers
13 (first author 0, last author 7)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 trial · 2019: none · 2020: 2 papers, 1 trial · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: none · 2026: 1 paper

Papers 13

  1. Human endogenous retroviruses as immune-related prognostic biomarkers in pancreatic cancer. Co-author DOI 10.1186/s12885-026-16373-9↗
  2. CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy. Last author DOI 10.1080/2162402x.2023.2294563↗
  3. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… Last author DOI 10.1200/jco.23.00795↗
  4. Interleukin-1α as a Potential Prognostic Biomarker in Pancreatic Cancer. Last author DOI 10.3390/biomedicines12061216↗
  5. Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery. Last author DOI 10.3390/biomedicines12122754↗
  6. SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features. Co-author DOI 10.1002/1878-0261.13370↗
  7. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
  8. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  9. Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. Co-author DOI 10.3390/cancers14071675↗
  10. Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma. Last author DOI 10.3390/cancers13081851↗
  11. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/j.ejca.2020.05.018↗
  12. Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. Last author DOI 10.21873/anticanres.14395↗
  13. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients wit… Last author PMID 22993372↗

Trials 2

  1. Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair G… Principal investigator NCT04169841↗
  2. OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients Principal investigator NCT04548960↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Caroline Truntzer · 5 shared papers, 2021–2024 · strength 0.99
  2. Angélique Vienot · 4 shared papers, 2023–2024 · strength 0.69
  3. Christophe Borg · 3 shared papers, 2023–2024 · strength 0.54
  4. Silvia Mihaela Ilie · 1 shared paper, 2026 · strength 0.36
  5. Paula Iuliana Toma · 1 shared paper, 2026 · strength 0.36
  6. Sylvain Manfrédi · 2 shared papers, 2022–2023 · strength 0.28
  7. Côme Lepage · 2 shared papers, 2022–2023 · strength 0.28
  8. Leonardo Gigante · 1 shared paper, 2024 · strength 0.28
  9. Jean‐Baptiste Bachet · 2 shared papers, 2023–2024 · strength 0.27
  10. Coralie Schoumacher · 1 shared paper, 2024 · strength 0.20
  11. Julie Lecuelle · 1 shared paper, 2021 · strength 0.17
  12. Gerlinde Avérous · 1 shared paper, 2023 · strength 0.16
  13. Anne‐Marie Bouvier · 1 shared paper, 2022 · strength 0.16
  14. Olivier Facy · 1 shared paper, 2022 · strength 0.16
  15. Valérie Jooste · 1 shared paper, 2022 · strength 0.16
  16. Yves Rinaldi · 1 shared paper, 2024 · strength 0.15
  17. Gaël S. Roth · 1 shared paper, 2024 · strength 0.15
  18. Cindy Neuzillet · 1 shared paper, 2024 · strength 0.15
  19. David Malka · 1 shared paper, 2024 · strength 0.15
  20. Christelle de la Fouchardière · 1 shared paper, 2024 · strength 0.15
  21. Nicolas Williet · 1 shared paper, 2024 · strength 0.15
  22. Olivier Bouché · 1 shared paper, 2024 · strength 0.15
  23. Jean-David Fumet · 1 shared paper, 2020 · strength 0.13
  24. Noelle K. LoConte · 1 shared paper, 2023 · strength 0.12
  25. Jerome F. Cros · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.